Log in

Relevant bibliographies by topics / Digestive System Neoplasms-therapy

Contents

Journal articles
Dissertations / Theses
Books

Academic literature on the topic 'Digestive System Neoplasms-therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Digestive System Neoplasms-therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Digestive System Neoplasms-therapy"

1

Wu, Qing, and Zhao-Shen Li. "Molecular targeted therapy of digestive system neoplasms." World Chinese Journal of Digestology 16, no. 32 (2008): 3666. http://dx.doi.org/10.11569/wcjd.v16.i32.3666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Feng, Wei, Zhangyao Su, Qingqing Yin, Wei Zong, Xianjuan Shen, and Shaoqing Ju. "ncRNAs associated with drug resistance and the therapy of digestive system neoplasms." Journal of Cellular Physiology 234, no. 11 (April 2, 2019): 19143–57. http://dx.doi.org/10.1002/jcp.28551.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Huang, Ying-Qiu. "Current progress in diagnosis and therapy of neuroendocrine neoplasms of the digestive system." World Chinese Journal of Digestology 24, no. 17 (2016): 2625. http://dx.doi.org/10.11569/wcjd.v24.i17.2625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zhan, Xianbao, Bin Wang, Yiran Wang, Longpei Chen, Xiaobo Peng, Jie Li, Meihong Wu, Linli Zhang, and Shuhui Tang. "Phase I trial of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e15269-e15269. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15269.

Full text

Abstract:

e15269 Background: Cancer cells have characteristics of genetic instabilities and accumulate somatic mutations rapidly which could produce tumor specific antigens (TSAs) called as neoantigens. As the cancer vaccine based on TSAs has potential to treat the disease, personalized neoantigen-based immunotherapies are emerging. We report for the first time that vaccines are used to treat advanced digestive system neoplasms. Methods: In this single-arm, open-label, first-in-human phase I pilot study (NCT03468244) to investigate the feasibility, safety, immunogenicity and clinical activity of personalized mRNA vaccine. Patients with advanced digestive system neoplasms received up to 20 stimulatory synthetic long peptides vaccine at a dose of 0.2 mg on days 1 and 0.8mg on days 2, administered subcutaneously of every 3 weeks(Q3W) for 12 weeks. Patients was treated with standard treatments according to NCCN guideline simultaneously. Adverse Event (AE) grade categorization is according to CTCAE 4.0, and tumor response was assessed per RECIST 1.1. Immune factors and ELISPOT assay were examined every 3 weeks after vaccination. Results: As of February 1st, 2020, three patients (52yrs, 47yrs and 52yrs; ECOG PS: 0) with advanced rectal, colon and gastric cancer completed the vaccine therapy for 3-4 cycles. There were no serious adverse events, treatment-related death or severe neurotoxicity occurred in the study. The most common treatment-emergent adverse event (TEAE) was erythema at injection sites in three patients. Vaccine combined standard treatments treatment was associated with G3/4 hematological side effects: leucopenia (18%); neutropenia (9%); anemia (0); thrombocytopenia (18%). Blood samples for immune monitoring (ELISPOT and intracellular cytokine staining [ICS]) were collected pre-dose and at weeks 3 and 12. The level of IL-1β, IL-2 receptor, IL-6, IL-8, IL-10, and TNF-α increased for all patients. Especially, IL-8 and IL-2R increased significantly for more than 800 times in the patient with rectal cancer and more than 4 times in the patient with gastric cancer after injection, respectively. The PFS were 3.2, 3.0 and 3.0 months and the OS were 9.1, 6.0 and 7.8 months, respectively. Best response was 2 SD and 1 PD. Conclusions: This clinical study indicated that personalized mRNA vaccine may be safe and could activate immune response in vivo which is convinced by ELISPOT assay in vitro. Further studies are indicated to explore the personalized mRNA vaccine in gastrointestinal cancer. Clinical trial information: NCT03468244 .

APA, Harvard, Vancouver, ISO, and other styles

5

Michalak, Łukasz, Magdalena Bulska, Karolina Strząbała, and Piotr Szcześniak. "Neopterin as a marker of cellular immunological response." Postępy Higieny i Medycyny Doświadczalnej 71, no. 1 (August 24, 2017): 0. http://dx.doi.org/10.5604/01.3001.0010.3851.

Full text

Abstract:

Neopterin is a pyrazino-pyrimidine compound that belongs to the pteridine group. It is known to be a biochemical marker associated with cell-mediated immunity. It is produced by human monocytes/macrophages and dendritic cells from guanosine triphosphate (GTP) upon stimulation with interferon gamma (IFNγ), which is released by activated limphocytes Th. Neopterin is a very important clinic parameter, though the physiological role has not been exactly definited thus far. The level of neopterin reflects the stage of activation of the cellular immune system, which is important in the pathogenesis and progression of various diseases. Measuring its concentration in body fluids is used in many different areas of modern medicine, such as infectious disease, gastroenterology, transplantology and transfusiology, rheumatology or oncology. In neurological, cardio-vascular and autoimmune diseases, cell-mediated immunity is also activated, which is proved by the elevated level of this marker. Measurements of neopterin concentrations are also helpful in monitoring the therapy of patients infected with the HIV virus or treated by using immunomudulating therapy. As a result of measuring levels of neopterin in patients with neoplasms of digestive tract, increased concentration was proved, but it is not routinely used in everyday clinic practice.

APA, Harvard, Vancouver, ISO, and other styles

6

CORA, Roxana, Adrian Florin GAL, Marian TAULESCU, Flaviu TᾸBᾸRAN, Raluca VIDRIGHINESCU, Gina Corina TOMA, and Cornel CǍTOI. "Immunohistochemical Characterization of Canine Lymphomas." Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Veterinary Medicine 74, no. 2 (November 26, 2017): 149. http://dx.doi.org/10.15835/buasvmcn-vm:0003.

Full text

Abstract:

Lymphomas occur by clonal expansion of lymphoid cells and have distinctive morphological and immunophenotypic features. Determination of canine lymphoma immunophenotype is useful for accurate prognosis and further therapy. In the suggested study, we performed an immunohistochemical evaluation of some cases with canine lymphoma diagnosed in the Department of Pathology (Faculty of Veterinary Medicine, Cluj-Napoca, Romania), in order to characterize them. The investigation included 39 dogs diagnosed with different anatomical forms of lymphoma, following necropsy analysis or assessment of biopsies. The diagnosis of lymphoma was confirmed by necropsy and histopathology (Hematoxylin-eosin stain) examinations. The collected specimens were analyzed by immunohistochemistry technique (automatic method) using the following antibodies: CD3, CD20, CD21 and CD79a. The analyzed neoplasms were characterized as follows: about 64.10% of cases were diagnosed as B-cell lymphomas, 33.34% of cases as T-cell lymphomas, whereas 2.56% of cases were null cell type lymphomas (neither B nor T). Most of multicentric (80%), mediastinal (60%) and primary central nervous system lymphomas (100%) had B immunophenotype, while the majority of cutaneous (80%) and digestive (100%) lymphomas had T immunophenotype. Immunohistochemical description of canine lymphomas can deliver some major details concerning their behavior and malignancy. Additionally, vital prognosis and efficacy of some therapeutic protocols are relying on the immunohistochemical features of canine lymphoma.

APA, Harvard, Vancouver, ISO, and other styles

7

Ionescu, Sînziana, Octavia-Luciana Madge, Ioana Robu, Eugen Brătucu, and Claudiu Daha. "Surgical Oncology in Romania: An Analysis of Research and Impact Based on Literature Search in PubMed and Web of Science." BioMed Research International 2021 (March 8, 2021): 1–7. http://dx.doi.org/10.1155/2021/5528582.

Full text

Abstract:

Background. With a long tradition and outstanding contributions over time, medical scientific research in Romania has experienced major changes in the last two decades, marked by an increase in scientific publications, originating especially from university centers and fostered by national regulations on publication standards required for professional promotion. This study is aimed at assessing the literature on surgical oncology in Romania, published by Romanian authors in journals indexed in international databases. Materials and Methods. A literature search was performed, focused on surgical oncology performed in Romania. Two databases, PubMed and Web of Science (WoS), were finally selected and included in the study, which included bibliometric parameters and subject analysis. Results. The PubMed search retrieved 464,295 articles being published in only 3 Romanian journals, Chirurgia, The Medical-Surgical Journal (Iasi), and Romanian Journal of Morphology and Embryology. The search of the Web of Science retrieved 494 records on the subject of surgical oncology in Romania, 449 of which were published after 1989. The 494 articles received 2,102 citations, 4.26 per year, and an overall Hirsch index of 21. Most articles were published in the same 3 Romanian journals as in PubMed. Neoplasms of the digestive system prevailed, followed by articles on general surgical oncology issues, cancer research, and therapy. Bucharest has the highest number of authors, followed by Cluj-Napoca and Iasi. Conclusion. Research originating from Romania in the field of surgical oncology is present and visible at an international level mainly through Romanian journals. Sustained effort is required from surgical oncology authors to be published in international journals on this subject, as it is the only way to increase global visibility and impact.

APA, Harvard, Vancouver, ISO, and other styles

8

Gonda, Kenji, Masahiko Shibata, Satoshi Suzuki, Izumi Nakamura, Kensuke Kumamoto, Tatsuo Shimura, and Seiichi Takenoshita. "Serum levels of vascular endothelial growth factor in patients with gastrointestinal cancers and correlation with malnutrition, immunosuppression involving MDSC, and systemic inflammation." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 514. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.514.

Full text

Abstract:

514 Background: Vascular endothelial growth factor (VEGF) reportedly plays an important role in the progression of malignant neoplasms, and have been reported to induce myeloid-derived suppressor cells (MDSC) that appears in cancer and inflammation. Methods: Blood samples were collected from 57 patients, including 8 with esophageal cancer, 20 with gastric cancer, 29 with colorectal cancer, and from 18 healthy volunteers. We measured serum concentrations of VEGF and analyzed correlations with nutritional damage, immune suppression and systemic inflammation. As markers of immune function, IL-12 production of PBMC and MDSC (CD 11b+, CD14-, CD33+) were measured. Serum concentrations of albumin and rapid turnover protein were measured as a marker of nutritional status. Results: A significant increase in serum levels was seen in patients with esophageal, gastric, and colorectal cancers compared to healthy volunteers. Levels of VEGF were inversely correlated with serum concentrations of albumin, prealbumin and retinol-binding protein. Serum concentrations of VEGF were inversely correlated with the production of interleukin (IL)-12 and correlated with MDSC. VEGF levels also correlated with neutrophil count and neutrophil/lymphocyte count, and correlated inversely with lymphocyte count. Serum VEGF levels were then divided about a cutoff of 500 pg/ml, with levels of prealbumin and retinol-binding protein significantly decreased in patients with higher VEGF levels. Stimulation index and IL-12 production were significantly decreased in the group with higher VEGF levels, and MDSC counts tended to be higher in this group. Conclusions: These results demonstrated that increased production of VEGF correlated with systemic inflammation, nutritional impairment and inhibition of cell-mediated immunity involving MDSCs. An inactivation of dendritic cells may be occurring by the activation of MDSC. Anti-VEGF therapy may be of importance in treating digestive system cancers.

APA, Harvard, Vancouver, ISO, and other styles

9

Capdevila, Jaume, Lisa Bodei, Philippa Davies, Vera Gorbounova, Robert T. Jensen, Ulrich P. Knigge, Guenter J. Krejs, et al. "Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms." Neuroendocrinology 108, no. 1 (August 28, 2018): 18–25. http://dx.doi.org/10.1159/000493319.

Full text

Abstract:

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

APA, Harvard, Vancouver, ISO, and other styles

10

Ni, Yang-Hong, Xia Zhao, and Wei Wang. "CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy." Current Gene Therapy 20, no. 2 (September 18, 2020): 109–26. http://dx.doi.org/10.2174/1566523220666200623170738.

Full text

Abstract:

CD24, is a mucin-like GPI-anchored molecules. By immunohistochemistry, it is widely detected in many solid tumors, such as breast cancers, genital system cancers, digestive system cancers, neural system cancers and so on. The functional roles of CD24 are either fulfilled by combination with ligands or participate in signal transduction, which mediate the initiation and progression of neoplasms. However, the character of CD24 remains to be intriguing because there are still opposite voices about the impact of CD24 on tumors. In preclinical studies, CD24 target therapies, including monoclonal antibodies, target silencing by RNA interference and immunotherapy, have shown us brighten futures on the anti-tumor application. Nevertheless, evidences based on clinical studies are urgently needed. Here, with expectancy to spark new ideas, we summarize the relevant studies about CD24 from a tumor perspective.

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Digestive System Neoplasms-therapy"

1

Hill, Susanna S. "Association of Race/Ethnicity and Population Density with Disparities in Timeliness of Rectal Cancer Therapy." eScholarship@UMMS, 2020. https://escholarship.umassmed.edu/gsbs_diss/1078.

Full text

Abstract:

Objective: Access to care is key to effective rectal cancer treatment. We hypothesized that ethnic/racial minorities living in high population density areas would have the greatest delays in cancer care compared to whites living in medium population density areas. Methods: Using 2004-2016 National Cancer DataBase data, we identified stage I-III patients with invasive rectal adenocarcinoma who underwent surgery. The data were analyzed by race/ethnicity (whites, blacks, or Hispanics) and population density (metropolitan or urban/rural). Multivariable ANCOVA was performed to evaluate the duration of time from diagnosis to surgery. Results: The study population consisted of 76,131 patients: 65,172 Non-Hispanic whites (NHW; 85.6%), 6,167 Non-Hispanic blacks (NHB; 8.1%), and 4,792 Hispanics (6.3%). Of these, 61,363 patients (80.6%) lived in metropolitan areas. Among direct-to-surgery patients, the greatest difference in mean time from diagnosis to surgery was 20.3 days (urban/rural NHW, 53.3 days, vs. metropolitan Hispanics, 73.6 days). Among patients receiving neoadjuvant therapy, the greatest difference in mean time from diagnosis to surgery was 18.8 days (urban/rural NHW, 136.9 days, vs. metropolitan NHB, 155.7 days). After multivariable adjustment for several socioeconomic and clinical factors, among direct-to-surgery patients, metropolitan Hispanics had a 16.5-day delay (95% CI 12.9-20.0) compared with urban/rural NHW. In patients receiving neoadjuvant therapy, metropolitan NHB had an 18.1-day delay (95% CI 16.1-20.0) compared to urban/rural NHW. Conclusion: The combination of high population density and racial/ethnic minority status was associated with delays in rectal cancer care that persisted after adjusting for other important factors. Understanding which populations are at risk and perceived obstacles to timely care will help inform interventions to minimize treatment access disparities.

APA, Harvard, Vancouver, ISO, and other styles

2

Smith, Jordan L. "Reversing Cancer Cell Fate: Driving Therapeutic Differentiation of Hepatoblastoma to Functional Hepatocyte-Like Cells." eScholarship@UMMS, 2020. https://escholarship.umassmed.edu/gsbs_diss/1067.

Full text

Abstract:

Background & Aims: Despite advances in surgical care and chemotherapeutic regimens, the five-year survival rate for Stage IV Hepatoblastoma (HB), the predominant pediatric liver tumor, remains at 27%. YAP1 and β-Catenin co-activation occurs in 80% of children’s HB; however, a lack of conditional genetic models precludes exploration of tumor maintenance and therapeutic targets. Thus, the clinical need for a targeted therapy remains unmet. Given the predominance of YAP1 and β-catenin activation in children’s tumors, I sought to evaluate YAP1 as a therapeutic target in HB. Approach & Results: Herein, I engineered the first conditional murine model of HB using hydrodynamic injection to deliver transposon plasmids encoding inducible YAP1S127A, constitutive β-CateninDelN90, and a luciferase reporter to murine liver. Tumor regression was evaluated using in vivo bioluminescent imaging, and tumor landscape characterized using RNA sequencing, ATAC sequencing and DNA foot-printing. Here I show that YAP1 withdrawal in mice mediates >90% tumor regression with survival for 230+ days. Mechanistically, YAP1 withdrawal promotes apoptosis in a subset of tumor cells and in remaining cells induces a cell fate switch driving therapeutic differentiation of HB tumors into Ki-67 negative “hbHep cells.” hbHep cells have hepatocyte-like morphology and partially restored mature hepatocyte gene expression. YAP1 withdrawal drives formation of hbHeps by modulating liver differentiation transcription factor (TF) occupancy. Indeed, tumor-derived hbHeps, consistent with their reprogrammed transcriptional landscape, regain partial hepatocyte function and can rescue liver damage in mice. Conclusions: YAP1 withdrawal, without modulation of oncogenic β-Catenin, significantly regresses hepatoblastoma, providing the first in vivo data to support YAP1 as a therapeutic target for HB. Modulating YAP1 expression alone is sufficient to drive long-term regression in hepatoblastoma because it promotes cell death in a subset of tumor cells and modulates transcription factor occupancy to reverse the fate of residual tumor cells to mimic functional hepatocytes.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Digestive System Neoplasms-therapy"

1

Cai, Qiang. Gastrointestinal malignancies: New innovative diagnostics and treatment. New Jersey: World Scientific, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Meyers, Morton A. Neoplasms of the digestive tract: Imaging, staging, and management. Edited by Meyers Morton A. Philadelphia: Lippincott-Raven, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mullin, Gerard E., and Mary Marian. Integrative nutrition therapy. Boca Raton: CRC Press, Taylor & Francis Group, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

1935-, Takahashi T., ed. Recent advances in management of digestive cancers: Proceedings of UICC Kyoto International Symposium on Recent Advances in Management of Digestive Cancers, March 31-April 2, 1993. Tokyo: Springer-Verlag, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Price, Tim. A diagnostic atlas of tumors of the upper aero-digestive tract: A transnasal video endoscopic approach. New York, NY: Informa Healthcare, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

R, Galle P., ed. Disease progression and disease prevention in hepatology and gastroenterology: Proceedings of the Falk Symposium 150 held in Berlin, Germany, October 3-4, 2005. Dordrecht: Springer, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Falk Symposium (150th 2005 Berlin, Germany). Disease progression and disease prevention in hepatology and gastroenterology: Proceedings of the Falk Symposium 150 held in Berlin, Germany, October 3-4, 2005. Dordrecht: Springer, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

L, Gandolfi, and Fukuda Morimichi, eds. Current trends in digestive ultrasonography. Basel: Karger, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Al, Benson, ed. Gastrointestinal oncology. Boston: Kluwer Academic, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Benson, A. B. Gastrointestinal Oncology (Cancer Treatment and Research). Springer, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!